Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. - Wikidata - awgldk - TriplyDB

Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.

Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.

http://www.wikidata.org/entity/Q39472834

about

Alloantibody Generation and Effector Function Following Sensitization to Human Leukocyte Antigen The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients Translational research in kidney transplantation and the role of patient engagement The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection The use of novel diagnostics to individualize immunosuppression following transplantation Late and chronic antibody-mediated rejection: main barrier to long term graft survival Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms.Antibody Subclass Repertoire and Graft Outcome Following Solid Organ Transplantation A Rationale for Age-Adapted Immunosuppression in Organ Transplantation The Complement System and Antibody-Mediated Transplant Rejection The Humoral Theory of Transplantation: Epitope Analysis and the Pathogenicity of HLA Antibodies.Posttransplant allosensitization in low immunological risk kidney and kidney-pancreas graft recipients An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.HLA sensitisation: can it be prevented?Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies Impact of ABO Incompatibility on the Development of Acute Antibody-Mediated Rejection in Kidney Transplant Recipients Presensitized to HLA.Utility of HLA Antibody Testing in Kidney Transplantation.Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study.Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival.Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients.Many de novo donor-specific antibodies recognize β2 -microglobulin-free, but not intact HLA heterodimers.Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation.The Association Between Broad Antigen HLA Mismatches, Eplet HLA Mismatches and Acute Rejection After Kidney Transplantation Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy.Old game, new players: Linking classical theories to new trends in transplant immunology.Application of Operational Tolerance Signatures Are Limited by Variability and Type of Immunosuppression in Renal Transplant Recipients: A Cross-Sectional Study.Antibodies to HLA Molecules Mimic Agonistic Stimulation to Trigger Vascular Cell Changes and Induce Allograft Injury Assessing immunologic risk factors in transplantation.The specificity of acute and chronic microvascular alterations in renal allografts.Is it time to give up with calcineurin inhibitors in kidney transplantation?HLA antibody screening in kidney transplantation: current guidelines.Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms.Through a glass darkly: seeking clarity in preventing late kidney transplant failure The increasing clinical importance of alloantibodies in kidney transplantation.Methodological aspects of anti-human leukocyte antigen antibody analysis in solid organ transplantation.Clinical relevance of HLA antibody monitoring after kidney transplantation.

P2860

Q26766411-B69E894E-070E-489E-8C49-D4318C89D96C Q26774993-A1D3AF7F-8F07-48BB-8889-0B468DC14B74 Q26778752-D360DF75-C460-404C-8ABB-2796C60BF4A2 Q26862195-D72EA9A2-E946-468F-A1A9-24D694011598 Q26864686-388B4E6D-8892-48DC-9133-F81840E58857 Q27006030-B1AC7296-71CC-4C53-8CDE-A5D3B21107F5 Q27314948-3913FBD6-2F13-4C15-B467-F338CD5D6020 Q28076193-0F0E04BF-20B4-41CE-A5E9-C3E8817E6CED Q28080954-4A72804E-F382-4466-A042-B76813F055E5 Q28087773-C42A8D3F-9A3A-4603-9203-A9C30D5E9D26 Q30397251-2B71E052-1034-4FD3-AC26-32164C1D56E6 Q33563056-91CAA0A7-B72B-4D85-A282-8D8880899FE6 Q33865743-E954532C-6AB6-4AB6-848E-1A3CA2E7E755 Q33930084-D13D41E9-CCFC-49C8-B2FB-BF5460D3C2C8 Q34753440-D164528A-8CBB-4662-AAB2-7A5677F31BE8 Q34995106-EB1DE04A-F14B-4ACD-846D-3BF0E33E9669 Q35097898-D8D46843-E8B6-4D81-BE3C-13DC0B79E8DE Q35228551-BB0413D8-E1B8-4DBD-BD85-85290080CB7F Q35511754-B690F8B8-F3C8-4F21-80E4-E3A62E5A7CCA Q35790601-3EF7A04C-4265-4843-AC6D-BE8BEFA43967 Q36246918-204990FA-6E67-4E51-B8F4-CABCE64A6E9D Q36509321-43B4A903-F26C-4AA5-ABC9-9B5959EA214E Q36514864-A39933E4-F487-4B63-BD5A-0B3E274E21BC Q36822826-6DB9E16B-91D1-4AD2-9618-D007123CFD46 Q37352506-200C3A9D-A19A-45B3-B870-8440DF7C98C3 Q37375622-C28E9540-18E1-4C20-BB39-2F10B9464CE0 Q37481157-1C5E5A3A-F6FB-4944-8EE0-95DA9CF202C3 Q37660263-8299F415-34AB-48F1-B166-C74D8741E947 Q37662989-45CE223F-757B-4774-9B21-7F31CF4C42B7 Q37715369-4CFF6338-6D76-4CCC-AE3F-11636533ECBD Q37720377-7A9E79A8-1129-4EEE-91F0-9654CD237D09 Q38131035-3C278F0B-C0A6-4C81-8B65-F325B1C4AEEC Q38151921-3F9E7810-BEED-437F-BE86-9C52D4585D64 Q38156847-22CF4A10-1B3E-499C-A924-56419D826769 Q38165753-F752CF35-0C23-4A8B-AC56-B8D0BF9C8D1C Q38169496-A663FA81-E843-4895-A998-20A392D5FEE3 Q38237365-E0FF0624-6481-475A-B079-3516E387740F Q38258153-31392E57-03DB-40E0-A843-8E38FEA89C5A Q38262909-899268B2-F03B-4F83-82D2-B9596408D849 Q38265563-9321F922-FB39-4E5D-969E-0ACFE363F350

P2860

Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.

http://www.wikidata.org/entity/Q39472834

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.

@en

Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.

@nl

type

label

Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.

@en

Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.

@nl

prefLabel

Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.

@en

Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.

@nl

P1433

Q39472834-9FA161A0-F799-4D60-85EB-48E56942A142

P1476

Q39472834-DCB97AE8-F427-4066-8DD9-610BAF4C8F6C

P2093

Q39472834-15D16211-9693-4395-9EA5-FC30954C5664

Q39472834-4032DB83-EB24-4AC7-A74A-B5AEFD3C727A

Q39472834-4530AA0E-E04A-40CE-8620-2AAB591203C9

Q39472834-642A1B70-275F-46BD-8760-B7FDC1ABA7DB

Q39472834-6C8F5629-37C3-4CAF-8FB0-A8DF61985E88

Q39472834-79005574-F700-426A-A631-36538A028A4F

Q39472834-7D2990B3-ED38-4B7E-938C-D2970AAD982D

Q39472834-81281D41-444C-4BE5-8327-F52279C3B444

Q39472834-91E77EAE-33BE-4AD7-9A84-456EC6A0AFA5

Q39472834-BD94CE5F-9197-46C8-B0D7-B6F8371035E1

P304

Q39472834-F0EE9D96-F545-46BE-8A02-3F0A075626B9

P31

Q39472834-C1BF5F2D-DE70-4F95-BD54-EA1FCA9B398E

P356

Q39472834-4B36EF44-33AD-41AB-89D1-20838D0CB24D

P433

Q39472834-DD487FA9-F2FD-4A61-94C7-D6E2B14C5E8E

P478

Q39472834-992993BD-3229-4BED-9442-6BC39EBBB430

P577

Q39472834-D34A7042-CCAC-4BD5-B25E-A0E6EE9B7C76

P698

Q39472834-A95EA26C-2148-454A-85D1-C862F12B7E1A

P356

TP.0B013E31827D62E3

P1433

Transplantation

P1476

Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.

@en

P2093

Carl E Haisch

http://www.w3.org/2001/XMLSchema#string

Karen Parker

http://www.w3.org/2001/XMLSchema#string

Kimberly P Briley

http://www.w3.org/2001/XMLSchema#string

Lorita M Rebellato

http://www.w3.org/2001/XMLSchema#string

Matthew J Everly

http://www.w3.org/2001/XMLSchema#string

Miyuki Ozawa

http://www.w3.org/2001/XMLSchema#string

Paul Bolin

http://www.w3.org/2001/XMLSchema#string

Paul G Catrou

http://www.w3.org/2001/XMLSchema#string

Paul I Terasaki

http://www.w3.org/2001/XMLSchema#string

Robert C Harland

http://www.w3.org/2001/XMLSchema#string

P304

410-417

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/TP.0B013E31827D62E3

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23380861

http://www.w3.org/2001/XMLSchema#string